Césarcaïne: Prilocaine or Bupivacaine for Spinal Anesthesiain Pregnant

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Unknown status
CT.gov ID
NCT03433976
Collaborator
Hopital Saint Roch (Other)
50
1
2
27.8
1.8

Study Details

Study Description

Brief Summary

The planned cesarean section is an intervention with a standard operating time of less than 40 minutes in trained teams. Hyperbaric Bupivacaine is the local anesthetic (LA) reference for these operations. But the duration of its motor block is generally greater than 3 hours. The purpose of this study is to show a reduction in motor block time with hyperbaric Prilocaine by at least 30 minutes, which would allow mothers and their children to return to the maternity ward earlier and thus improve the circulation of patients within the maternity's PACU.

Condition or Disease Intervention/Treatment Phase
  • Drug: spinal anesthesia
Phase 2

Detailed Description

Prospective study, randomized into two parallel groups (Hyperbaric Prilocaïne versus hyperbaric Bupivacaine), double-blind, monocentric (Clinique Saint Roch in Montpellier).

The number of subjects required is 50 patients, 25 per group.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Comparison of the Duration of Motor Block After Spinal Anesthesia for Planned Cesarean Sections: Hyperbaric Prilocaïne Versus Hyperbaric Bupivacaine
Actual Study Start Date :
May 7, 2018
Anticipated Primary Completion Date :
May 7, 2020
Anticipated Study Completion Date :
Aug 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Other: Hyperbaric Bupivacaine

spinal anesthesia for planned cesarean sections control group

Drug: spinal anesthesia
spinal anesthesia for planned cesarean sections

Active Comparator: Hyperbaric Prilocaïne

spinal anesthesia for planned cesarean sections

Drug: spinal anesthesia
spinal anesthesia for planned cesarean sections

Outcome Measures

Primary Outcome Measures

  1. duration of motor block [up to 6 hours]

    To compare the duration of motor block after spinal anesthesia with hyperbaric Prilocaïne versus hyperbaric Bupivacaine This evaluation is done every 15 min from the entrance to the recovery room (PACU); the motor block stops being evaluated when the modified bromination score reaches 4

Secondary Outcome Measures

  1. The upper sensory level [15 minutes after the LA injection]

    The upper sensory level obtained 15 minutes after the LA injection

  2. Hypotensive episodes [1 day]

    Hypotensive episodes

  3. The time between injection and incision [1 day]

    The time between injection and incision

  4. The duration of the intervention [1 day]

    The duration of the intervention

  5. The time to return to the standard maternity ward [1 day]

    The time to return to the standard maternity ward

  6. APGAR score of newborns at birth [1 day]

    APGAR score of newborns at birth. L'APGAR Apgar score is a method to quickly summarize the health of newborn children. The Apgar scale is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. The five criteria are summarized using words chosen to form a backronym (Appearance, Pulse, Grimace, Activity, Respiration). The test is generally done at one and five minutes after birth, and may be repeated later if the score is and remains low. Scores 7 and above are generally normal, 4 to 6 fairly low, and 3 and below are generally regarded as critically low.

  7. The delay between spinal anesthesia and the first emergency analgesic injection [1 day]

    The delay between spinal anesthesia and the first emergency analgesic injection

  8. Assessment of pain (VAS) [1 day]

    Pain on arrival and departure of PACU and at 24 hours. Pain will be assessedby VAS (Visual Analogue Scale); Patients rate pain on VAS from 0-10, 0 being no pain and 10 being the worst pain imaginable..

  9. The delay between spinal anesthesia and the first injection of second-line analgesia [1 day]

    The delay between spinal anesthesia and the first injection of second-line analgesia : delay between spinal anesthesia ans the need of rescue analgesia

  10. The presence of neuro-sensory disorders within 24 hours postoperatively [1 day]

    The presence of neuro-sensory disorders within 24 hours postoperatively

  11. The presence of post lumbar puncture syndrome [1 day]

    The presence of post lumbar puncture syndrome

  12. score de satisfaction [1 day]

    Patient satisfaction score at 24 hours will be assessed by VAS (Visual Analogue Scale); Patients rate satisfaction on VAS from 0-10, 0 being no satisfaction and 10 being total satisfaction

  13. Statifaction of the Surgeon [1 day]

    The surgeon assessed his satisfaction while the cesarien section. The surgeon satisfaction score at 24 hours will be assessed by VAS (Visual Analogue Scale); Surgeon rate satisfaction on VAS from 0-10, 0 being no satisfaction and 10 being total satisfaction.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Normal pregnancy

  • Scheduled caesarean section

  • Non-multiple pregnancy

  • Age of patient: 18 years and over

  • Height of patient: between 155 and 175 cm

  • Affiliated patients or beneficiaries of a Social Security System

  • Signature of the patient's consent

Exclusion criteria:
  • Patient <18 years

  • Pathological pregnancy

  • Multiple pregnancy

  • Emergency caesarean

  • Patients who cannot give informed consent (not French speaking)

  • Refusal of the patient

  • Contraindications to spinal anesthesia

  • Contraindications to Prilocaine

  • Contraindications to Bupivacaine

Contacts and Locations

Locations

Site City State Country Postal Code
1 Uhmontpellier Montpellier France 34295

Sponsors and Collaborators

  • University Hospital, Montpellier
  • Hopital Saint Roch

Investigators

  • Principal Investigator: christophe DADURE, University Hospital, Montpellier

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Montpellier
ClinicalTrials.gov Identifier:
NCT03433976
Other Study ID Numbers:
  • UF9859
First Posted:
Feb 15, 2018
Last Update Posted:
Dec 11, 2018
Last Verified:
Mar 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Montpellier
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 11, 2018